RGD-Binding Integrins in Head and Neck Cancers
- PMID: 28587135
- PMCID: PMC5483875
- DOI: 10.3390/cancers9060056
RGD-Binding Integrins in Head and Neck Cancers
Abstract
Alterations in integrin expression and function promote tumour growth, invasion, metastasis and neoangiogenesis. Head and neck cancers are highly vascular tumours with a tendency to metastasise. They express a wide range of integrin receptors. Expression of the αv and β1 subunits has been explored relatively extensively and linked to tumour progression and metastasis. Individual receptors αvβ3 and αvβ5 have proved popular targets for diagnostic and therapeutic agents but lesser studied receptors, such as αvβ6, αvβ8, and β1 subfamily members, also show promise. This review presents the current knowledge of integrin expression and function in squamous cell carcinoma of the head and neck (HNSCC), with a particular focus on the arginine-glycine-aspartate (RGD)-binding integrins, in order to highlight the potential of integrins as targets for personalised tumour-specific identification and therapy.
Keywords: arginine-glycine-aspartate (RGD); integrin αv; metastasis; treatment resistance; β1; β3; β6.
Conflict of interest statement
The authors declare no conflict of interest.
References
-
- Global Burden of Disease Cancer Collaboration Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524–548. - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
